Table 1 Baseline characteristics of the unmatched and matched groups
Characteristic | Before Propensity Score Matching | After Propensity Score Matching | ||||
|---|---|---|---|---|---|---|
TKIs | TKIs + SBRT | p value | TKIs | TKIs + SBRT | p value | |
NO. of patients | 262 | 46 | 90 | 45 | ||
Median age years (range) | 60.0 (22–87) | 59.5 (25–85) | 0.843 | 58.0 (32–83) | 59.0 (25–85) | 0.614 |
Sex | 0.775 | 0.902 | ||||
Female | 154 (58.8%) | 26 (56.5%) | 51 (56.7%) | 25 (55.6%) | ||
Male | 108 (41.2%) | 20 (43.5%) | 39 (43.3%) | 20 (44.4%) | ||
Smoking status | 0.877 | 0.439 | ||||
Never | 185 (70.6%) | 33 (71.7%) | 58 (64.4%) | 32 (71.1%) | ||
Former or current | 77 (29.4%) | 13 (28.3%) | 32 (35.6%) | 13 (28.9%) | ||
ECOG status | 0.462 | 0.236 | ||||
0–1 | 210 (80.2%) | 39 (84.8%) | 68 (75.6%) | 38 (84.4%) | ||
2–3 | 52 (19.8%) | 7 (15.2%) | 22 (24.4%) | 7 (15.6%) | ||
Prior radical resection | 0.968 | 0.249 | ||||
No | 233 (88.9%) | 41 (89.1%) | 73 (81.1%) | 40 (88.9%) | ||
Yes | 29 (11.1%) | 5 (10.9%) | 17 (18.9%) | 5 (11.1%) | ||
Histological type | 0.482 | 0.392 | ||||
Adenocarcinoma | 245 (93.5%) | 45 (97.8%) | 88 (97.8%) | 44 (97.8%) | ||
Adenosquamous carcinoma | 8 (3.1%) | 0 (0.0%) | 1 (1.1%) | 0 (0.0%) | ||
Not otherwise specified | 4 (1.5%) | 1 (2.2%) | 0 (0.0%) | 1 (2.2%) | ||
Squamous carcinoma | 5 (1.9%) | 0 (0.0%) | 1 (1.1%) | 0 (0.0%) | ||
Clinical stage | 0.372 | 0.514 | ||||
III | 18 (6.9%) | 1 (2.2%) | 0 (0.0%) | 0 (0.0%) | ||
IVa | 36 (13.7%) | 10 (21.7%) | 18 (20.0%) | 10 (22.2%) | ||
IVb | 179 (68.3%) | 30 (65.2%) | 55 (61.1%) | 30 (66.7%) | ||
Recurrence | 29 (11.1%) | 5 (10.9%) | 17 (18.9%) | 5 (11.1%) | ||
Brain metastasis | 0.381 | 0.143 | ||||
No | 147 (56.1%) | 29 (63.0%) | 44 (48.9%) | 28 (62.2%) | ||
Yes | 115 (43.9%) | 17 (37.0%) | 46 (51.1%) | 17 (37.8%) | ||
Metastatic status | 0.033 | 0.43 | ||||
Polymetastasis | 129 (52.9%) | 16 (35.6%) | 26 (28.9%) | 16 (35.6%) | ||
Oligometastasis | 115 (47.1%) | 29 (64.4%) | 64 (71.1%) | 29 (64.4%) | ||
EGFR mutations | 0.748 | 0.787 | ||||
Exon19 deletion | 146 (55.7%) | 23 (50.0%) | 51 (56.7%) | 23 (51.1%) | ||
L858R mutation | 104 (39.7%) | 21 (45.7%) | 34 (37.8%) | 20 (44.4%) | ||
Other | 12 (4.6%) | 2 (4.3%) | 5 (5.6%) | 2 (4.4%) | ||
Type of EGFR TKIs | 0.863 | 0.611 | ||||
Gefitnib | 152 (58.0%) | 29 (63.0%) | 53 (58.9%) | 28 (62.2%) | ||
Erlotinib | 28 (10.7%) | 3 (6.5%) | 14 (15.6%) | 3 (6.7%) | ||
Osimertinib | 26 (9.9%) | 5 (10.9%) | 10 (11.1%) | 5 (11.1%) | ||
Icotinib | 48 (18.3%) | 7 (15.2%) | 11 (12.2%) | 7 (15.6%) | ||
Afatinib | 8 (3.1%) | 2 (4.3%) | 2 (2.2%) | 2 (4.4%) | ||
No. of lines of TKIs therapy | 0.022 | 0.361 | ||||
1 | 232 (88.5%) | 35 (76.1%) | 74 (82.2%) | 34 (75.6%) | ||
2 | 30 (11.5%) | 11 (23.9%) | 16 (17.8%) | 11 (24.4%) | ||